{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:41:57Z","timestamp":1789731717247,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.anai.2022.02.017","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T02:22:24Z","timestamp":1646187744000},"page":"669-676.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study"],"prefix":"10.1016","volume":"128","author":[{"given":"Yen","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna D.","family":"Carstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"C21","key":"10.1016\/j.anai.2022.02.017_bib0001","first-page":"1","article-title":"Characterization of eosinophilic and non-eosinophilic severe asthma phenotypes and proportion of patients with these phenotypes in the International Severe Asthma Registry (ISAR)","volume":"201","author":"Perez-de-Llano","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2022.02.017_bib0002","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2022.02.017_bib0003","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jaip.2017.05.001","article-title":"Asthma exacerbations: pathogenesis, prevention, and treatment","volume":"5","author":"Castillo","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2022.02.017_bib0004","series-title":"Global Strategy for Asthma Management and Prevention","year":"2022"},{"key":"10.1016\/j.anai.2022.02.017_bib0005","unstructured":"National Heart Lung and Blood Institute. Guidelines for the Diagnosis and Management of Asthma. 2007. Available at: https:\/\/www.nhlbi.nih.gov\/guidelines\/asthma\/asthgdln.htm. Accessed April 29, 2021."},{"issue":"1","key":"10.1016\/j.anai.2022.02.017_bib0006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anai.2014.04.011","article-title":"High blood eosinophil count is associated with more frequent asthma attacks in asthma patients","volume":"113","author":"Tran","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.017_bib0007","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.anai.2022.02.017_bib0008","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/02770903.2018.1534967","article-title":"The prevalence and disease burden of severe eosinophilic asthma in Japan","volume":"56","author":"Nagasaki","year":"2019","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.anai.2022.02.017_bib0009","doi-asserted-by":"crossref","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"de Groot","year":"2015","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.anai.2022.02.017_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.anai.2022.02.017_bib0011","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.anai.2018.07.033","article-title":"Selecting the right biologic for your patients with severe asthma","volume":"121","author":"Manka","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.02.017_bib0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-018-0876-8","article-title":"Benralizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.anai.2022.02.017_bib0013","unstructured":"US Food and Drug Administration. Prescribing information for Fasenra (Benralizumab). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761070s000lbl.pdf. Accessed April 29, 2021."},{"issue":"10056","key":"10.1016\/j.anai.2022.02.017_bib0014","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.anai.2022.02.017_bib0015","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.anai.2022.02.017_bib0016","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.017_bib0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2022.02.017_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00467-010-1699-3","article-title":"Pathogenesis, diagnosis and management of hyperkalemia","volume":"26","author":"Lehnhardt","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.anai.2022.02.017_bib0019","unstructured":"United States Department of Labor, Bureau of Labor Statistics. Consumer price index - all urban consumers. Available at: https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM. Accessed January 22, 2021."},{"issue":"11","key":"10.1016\/j.anai.2022.02.017_bib0020","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.anai.2022.02.017_bib0021","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.017_bib0022","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.anai.2022.02.017_bib0023","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","article-title":"Real-life experience with benralizumab during 6 months","volume":"20","author":"Padilla-Galo","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.anai.2022.02.017_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2020.12.049","article-title":"Elimination of oral corticosteroids (OCS) with benralizumab treatment in OCS-dependent asthmatics using a rapid, personalized algorithm: the PONENTE trial","volume":"147","author":"Menzies-Gow","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.02.017_bib0025","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2012.01.039","article-title":"Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma","volume":"129","author":"Ivanova","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.anai.2022.02.017_bib0026","first-page":"S7","article-title":"Epidemiology and economic burden of asthma","volume":"5","author":"Loftus","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anai.2022.02.017_bib0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2466-9-24","article-title":"Economic burden of asthma: a systematic review","volume":"9","author":"Bahadori","year":"2009","journal-title":"BMC Pulm Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622001314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622001314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:28:34Z","timestamp":1761053314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622001314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1081120622001314"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.02.017","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}